The Oncology Institute, Inc. shares rise 1.70% intraday after Guardant Health's positive clinical readout update for its Shield™ blood test.

The Oncology Institute, Inc. rose 1.70% during intraday trading, following the announcement by Guardant Health, Inc. of a positive clinical readout update for its Shield™ blood test. The new colorectal cancer (CRC) screening algorithm (V2) met all primary endpoints, with an 84% sensitivity and 90% specificity for detecting CRC. The sensitivity for detecting stage I CRC was 62%, which was highlighted as a significant achievement by Guardant Health co-CEO AmirAli Talasaz.